TG Therapeutics Shares Fall on EPS Miss Despite Strong BRIUMVI Sales and Raised Guidance
TG Therapeutics saw strong BRIUMVI sales and raised forecasts, but higher costs caused a major earnings miss, pushing shares lower.
/ 3 items
#TGTX↓
Briumvi’s New Subcutaneous Formulation Boosts TG Therapeutics Stock
TG Therapeutics stock rose after early trial results showed its under-skin MS drug worked well and may allow at-home dosing.
TG Therapeutics Stock Rises on Strong Briumvi Sales and Raised Guidance
TG Therapeutics (TGTX) boosts 2025 revenue forecast to $616M on strong Briumvi MS drug sales, projects $875M-$900M for 2026, exceeding Wall Street expectations.